32058-78-9

Upstream product

• 25843-69-0 N-phenylanthranilic acid hydrazide 

Downstream Products

• 1449224-28-5 C₁₉H₂₂N₄OS 
• 1449224-29-6 C₂₀H₂₂N₄OS 
• 1449224-30-9 C₂₀H₂₃N₅OS 
• 1449224-31-0 C₁₉H₂₀N₄O₂S 
• 1449224-32-1 C₂₁H₁₈N₄OS 
• 1449224-33-2 C₂₂H₂₀N₄OS 
• 1449224-34-3 C₂₃H₂₀N₄O₂S 
• 1449224-35-4 C₂₁H₁₇FN₄OS 
• 1449224-36-5 C₂₁H₁₇ClN₄OS 
• 1449224-37-6 C₂₁H₁₇BrN₄OS 
• 1449224-38-7 C₂₂H₂₀N₄O₂S 
• 1449224-39-8 C₂₁H₁₉N₅O₃S₂ 
• 1449224-40-1 C₂₂H₁₇N₅OS₂ 
• 1449224-26-3 C₁₆H₁₅N₃OS 

Relevant academic research and scientific papers

Synthesis, quantitative structure-activity relationship and biological evaluation of 1*3*4-oxadiazole derivatives possessing diphenylamine moiety as potential anticancer agents

Synthesis of 2,5-disubstituted-1,3,4-oxadiazole (2a-c), 3-substituted aminomethyl-5-substituted-1,3,4- oxadiazole-2(3H)-thione (4a-m) and 2-substituted thio-5-substituted-1,3,4-oxadiazole (5a, b) had been described. All the synthesized derivatives were screened for anticancer activity against HT29 and MCF7 cancer cell lines using Sulfo-Rodamine B (SRB) standard method. Most of the tested compounds exploited potent antiproliferative activity against HT29 cancer cell line rather than MCF7 cancer cell line. Compounds 2a-c, 4f and 5a exhibited potent cytotoxicity (IC50 1.3-2.0 μm) and selectivity against HT29 cancer cell line. Quantitative structure-activity relationship (QSAR) study was applied to find a correlation between the experimental antiproliferative activities of the newly synthesized oxadiazole derivatives with their physicochemical parameter and topological index.